Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma
Open Access
Abstract
Cyclin D1, a critical cyclin-dependent kinase (CDK) 4/6-dependent regulator of G1/S transition, has attracted much interest as a therapeutic target. The cyclin D1 expression in small intestinal adenocarcinomas (SIACs) has not yet been comprehensively studied, owing to the rarity of this tumor. We investigated the clinicopathological and prognostic significance of the cyclin D1 expression in 232 surgically resected primary SIACs through a multi-institutional study. A high expression of cyclin D1 (cyclin D1High) was detected in 145 SIAC cases (63%), which was significantly higher than that in normal small intestinal mucosa (11%). Cyclin D1High was more commonly found in SIACs with a lower T-category and disease stage and KRAS mutation and predicted better patient survival. Multivariate analysis revealed that cyclin D1High, the absence of retroperitoneal seeding and lymphovascular invasion, and the lower N-category were identified as independent prognostic indicators for patients with SIACs. Specifically, cyclin D1High affected patient survival in the lower stage group (stages I and II). In conclusion, cyclin D1 was commonly overexpressed in SIACs, and cyclin D1High acted as a favorable prognostic indicator in patients with SIACs. These findings in SIACs may, thus, be important to further comprehend the mechanism of cyclin D1 in carcinogenesis and to strategize appropriate patient therapies.Keywords
Funding Information
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2021R1A2C1003898)
- Translational R&D Project through Institute for Bio-Medical Convergence, Incheon St. Mary’s Hospital, The Catholic University of Korea (2021R1A2C1003898)
This publication has 62 references indexed in Scilit:
- Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic ModelsCancer Prevention Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significanceJournal of Cancer Research and Clinical Oncology, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer CasesClinical Cancer Research, 2009
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomasMolecular Cancer Therapeutics, 2008
- Cyclin D1 Overexpression and Response to Bortezomib Treatment in a Breast Cancer ModelJNCI: Journal of the National Cancer Institute, 2006
- Antibody Selection in Immunohistochemical Detection of Cyclin D1 in Mantle Cell LymphomaAmerican Journal of Clinical Pathology, 2005
- Antibody Selection in Immunohistochemical Detection of Cyclin D1 in Mantle Cell LymphomaAmerican Journal of Clinical Pathology, 2005
- Expression of non‐membranous β‐catenin and γ‐catenin, c‐Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomasAPMIS, 2004